Lin Wu
Hunan Cancer Hospital
5
3
1
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Zhengfei Zhu, MD
Fudan University
Shared therapeutic areas:
Worked with same sponsors:
Zhenzhou Yang
The Second Affiliated Hospital of Chongqing Medical University
Shared therapeutic areas:
Worked with same sponsors:
Yanyang Wang
General Hospital of Ningxia Medical University
Shared therapeutic areas:
Worked with same sponsors:
Jichen Ren
Jilin Provincial Tumor Hospital
Shared therapeutic areas:
Worked with same sponsors:
Dejun XIng
Jilin Provincial Tumor Hospital
Shared therapeutic areas:
Worked with same sponsors:
Hongqing Zhuang
Peking University Third Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jinjun Ye
Jiangsu Cancer Institute & Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jiancheng Li
Fujian Cancer Hospital
Shared therapeutic areas:
Worked with same sponsors:
Anwen Liu
Second Affiliated Hospital of Nanchang University
Shared therapeutic areas:
Worked with same sponsors:
Xiaojia Cui
The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma
Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
All 5 trials loaded